Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Specimen Handling 108Magnetic Resonance Spectroscopy 77Biopsy 76pembrolizumab 59Cyclophosphamide 49fludarabine 40Carboplatin 25Nivolumab 24Cetuximab 23venetoclax 21Radiotherapy 21Cisplatin 21Bevacizumab 20atezolizumab 18X-Rays 18Radiation 17Ipilimumab 17fludarabine phosphate 16Fluorouracil 16Gemcitabine 15Temozolomide 14Paclitaxel 14Leucovorin 14Irinotecan 14Cytarabine 14durvalumab 13Pemetrexed 13Azacitidine 13Oxaliplatin 12CTLA-4 Antigen 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × axatilimab × 30 days × Clear all
NCT06959537 2026-05-20

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡